EGFR and cancer: In addition, acrylamide-based anticancer agents showed great potential for the treatment of cancer by induction of cell cycle arrest, differentiation, and cellular apoptosis.25,26 Afatinib, an acrylamide-containing drug, is an EGFR kinase inhibitor indicated for the treatment of adult patients with metastatic, non-small lung cancer.27 It covalently binds to the kinase domain of EGFR and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of EGFR downstream signaling.28